News & Events about Akebia Therapeutics Inc.
Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA Akebia Therapeutics Received Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA PR Newswire...
Akebia Therapeutics (NASDAQ:AKBA Get Rating) and Generation Bio (NASDAQ:GBIO Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, ...
Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 Akebia Therapeutics Announces Poster Presentation at ASN Kidney Week 2022 PR Newswire CAMBRIDGE, Mass., Oct. 21, 2022 CAMBRIDGE, Mass., Oct. 21, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a...
Ticker Report
4 months ago
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA Get Rating) have been assigned an average recommendation of Hold from the seven brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation. The ...
Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire CAMBRIDGE, Mass., Sept. 1, 2022 CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire...